A prospective study to assess the screening value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for the identification of patients that benefit from additional cardiac testing prior to vascular surgery.
Recruiting
- Conditions
- Perioperative cardiac risk stratification1001108210003184
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1000
Inclusion Criteria
Patients with peripheral vascular atherosclerosis scheduled for vascular surgery involving either; a) revascularization utilizing aortic or proximal lower extremity procedures, or b) distal lower extremity vascular reconstruction, are eligible to participate.
Exclusion Criteria
No written informed consent.
Unstable coronary disease.
Undergoing emergency surgery.
Previous participation in the DECREASE VI trial.
Reoperation within 30 days of an initial surgical procedure.
Participation in another clinical trial within the last 30 days.
Age <18 years
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of this trial is to validate the screening potential of<br /><br>NT-proBNP in a population of low to intermediate risk patients, i.e. patients<br /><br>with zero to two cardiac risk factors, scheduled for vascular surgery.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary objective is to identify prior to vascular surgery high risk<br /><br>patients, with three or more cardiac risk factors, with a normal stress test.</p><br>